Annovis Bio Inc logo

ANVS

Annovis Bio Inc

$12.11

Earnings Summary

Revenue
$0Mn
Net Profits
$-5.89Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Annovis Bio Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Annovis Bio Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Annovis Bio Inc’s net profit fell -84.21% since last year same period to $-5.89Mn in the Q1 2022. On a quarterly growth basis, Annovis Bio Inc has generated 99.96% jump in its net profits since last 3-months.

Net Profit Margins:

Annovis Bio Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Annovis Bio Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Annovis Bio Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.58
EPS Estimate Current Year
-0.58

Highlights

EPS Estimate Current Quarter:

Annovis Bio Inc’s earning per share (EPS) estimates for the current quarter stand at -0.58 - a -132% fall from last quarter’s estimates.

EPS Estimate Current Year:

Annovis Bio Inc’s earning per share (EPS) estimates for the current year stand at -0.58.

Key Ratios

Key ratios of the Annovis Bio Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.72
Return on Assets (ROA)
-0.34
Return on Equity (ROE)
-0.56
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Annovis Bio Inc’s earning per share (EPS) fell -56.52% since last year same period to -0.72 in the Q1 2022. This indicates that the Annovis Bio Inc has generated -56.52% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Annovis Bio Inc’s return on assets (ROA) stands at -0.34.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Annovis Bio Inc’s return on equity (ROE) stands at -0.56.

Dividend Per Share (DPS):

Annovis Bio Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-04
-0.58
-0.72
-24.14%

Company Information

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). The Comapny's believes that it is the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The Company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. The Company has two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients.

Organisation
Annovis Bio Inc
Headquarters
Berwyn, Pennsylvania, US
Employees
2
Industry
Electronic Equipment/Instruments
CEO
Maria Maccecchini